Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00384176 · ClinicalTrials.gov registry record · Phase 2
First Line Metastatic Colorectal Cancer Therapy in Combination With FOLFOX
A Phase 2 study, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 2
- Development phase
- 1,814
- Enrollment target
NCT00384176 is a Phase 2 study that has completed, run by AstraZeneca. The registered enrollment target is 1,814 participants.
The verdict
NCT00384176, a Phase 2 study, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 1,814 participants
- Enrollment target
Study Summary
The purpose of this study is to see if Cediranib in combination with FOLFOX is effective in treating metastatic colorectal cancer and to see how it compares with Avastin (Bevacizumab) in combination with FOLFOX.
Interventions
- DRUG Bevacizumab
- DRUG Cediranib
- DRUG 5-fluorouracil ( in FOLFOX)
- DRUG Leucovorin (in FOLFOX)
- DRUG Oxaliplatin (in FOLFOX)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,814 participants |
| Start Date | 2006-08-30 |
| Est. Completion | 2015-08-19 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00384176
The ClinicalTrials.gov registry entry for NCT00384176 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 1,814 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Bevacizumab is the first listed.
NCT00384176 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00384176 about?
NCT00384176 is a clinical study titled "First Line Metastatic Colorectal Cancer Therapy in Combination With FOLFOX". The purpose of this study is to see if Cediranib in combination with FOLFOX is effective in treating metastatic colorectal cancer and to see how it compares with Avastin (Bevacizumab) in combination with FOLFOX.
What is the current status of trial NCT00384176?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 1,814 participants. The study started on 2006-08-30. Estimated completion is 2015-08-19.
What interventions are being tested in trial NCT00384176?
The interventions under investigation include: Bevacizumab (DRUG), Cediranib (DRUG), 5-fluorouracil ( in FOLFOX) (DRUG), Leucovorin (in FOLFOX) (DRUG), Oxaliplatin (in FOLFOX) (DRUG).
Who is sponsoring clinical trial NCT00384176?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.